Abstract
Neuroimaging findings in people at either genetic risk or at clinical high-risk for psychosis (CHR-P) or bipolar disorder (CHR-B) remain unclear. A meta-analytic review of whole-brain voxel-based morphometry (VBM) and functional magnetic resonance imaging (fMRI) studies in individuals with genetic risk or CHR-P or CHR-B and controls identified 94 datasets (N = 7942). Notwithstanding no significant findings were observed following adjustment for multiple comparisons, several findings were noted at a more liberal threshold. Subjects at genetic risk for schizophrenia or bipolar disorder or at CHR-P exhibited lower gray matter (GM) volumes in the gyrus rectus (Hedges' g = −0.19). Genetic risk for psychosis was associated with GM reductions in the right cerebellum and left amygdala. CHR-P was associated with decreased GM volumes in the frontal superior gyrus and hypoactivation in the right precuneus, the superior frontal gyrus and the right inferior frontal gyrus. Genetic and CHR-P were associated with small structural and functional alterations involving regions implicated in psychosis. Further neuroimaging studies in individuals with genetic or CHR-B are warranted.
Original language | English |
---|---|
Article number | 110540 |
Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
Volume | 117 |
DOIs | |
State | Published - 13 Jul 2022 |
Externally published | Yes |
Keywords
- Bipolar disorder
- Meta-analysis
- Neuroimaging
- Psychiatry
- Psychosis
- Schizophrenia
Access to Document
Fingerprint
Dive into the research topics of 'A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder. / Luna, Licia P.; Radua, Joaquim; Fortea, Lydia et al.
In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 117, 110540, 13.07.2022.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder
AU - Luna, Licia P.
AU - Radua, Joaquim
AU - Fortea, Lydia
AU - Sugranyes, Gisela
AU - Fortea, Adriana
AU - Fusar-Poli, Paolo
AU - Smith, Lee
AU - Firth, Joseph
AU - Shin, Jae Il
AU - Brunoni, Andre R.
AU - Husain, Muhammad I.
AU - Husian, Muhammad O.
AU - Sair, Haris I.
AU - Mendes, Walber O.
AU - Uchoa, Luiz Ricardo A.
AU - Berk, Michael
AU - Maes, Michael
AU - Daskalakis, Zafiris J.
AU - Frangou, Sophia
AU - Fornaro, Michele
AU - Vieta, Eduard
AU - Stubbs, Brendon
AU - Solmi, Marco
AU - Carvalho, Andre F.
N1 - Funding Information: We are grateful to all participants who took part in the individual studies included in our systematic review and meta-analysis. Dr. Lícia P. Luna reports no conflicts of interest. Dr. Joaquim Radua reports no conflicts of interest. Dr. Lydia Fortea reports no conflicts of interest. Dr. Gisela Sugranyes reports no conflicts of interest. Dr. Adriana Fortea reports no conflicts of interest. Dr. Paolo Fusar-Poli has received grant fees from Lundbeck and honoraria fees from Lundbeck, Angelini and Menarini, outside the current work. Dr. Lee Smith reports no conflicts of interest. Dr. Joseph Firth is currently supported by a University of Manchester Presidential Fellowship ( P123958 ) and a UK Research and Innovation Future Leaders Fellowship ( MR/T021780/1 ) and has received support from a NICM-Blackmores Institute Fellowship . Dr. Jae Il Shin reports no conflicts of interest. Dr. Andre R. Brunoni reports no conflicts of interest. Dr. Muhammad I. Husain reports no conflicts of interest. Dr. Muhammad O. Husian reports no conflicts of interest. Dr. Haris I. Sair reports no conflicts of interest. Dr. Walber O. Mendes reports no conflicts of interest. Luiz Ricardo A. Uchoa reports no conflicts of interest. Dr. Michael Berk is supported by a NHMRC Senior Principal Research Fellowship ( 1059660 and 1156072 ). Dr. Michael Berk has received Grant/Research Support from the NIH , Cooperative Research Centre , Simons Autism Foundation , Cancer Council of Victoria , Stanley Medical Research Foundation , Medical Benefits Fund , National Health and Medical Research Council , Medical Research Futures Fund , Beyond Blue , Rotary Health , A2 milk company , Meat and Livestock Board , Woolworths , Avant and the Harry Windsor Foundation , has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. Dr. Michael Maes reports no conflicts of interest. Dr. Zafiris J Daskalakis reports no conflicts of interest. Dr. Sophia Frangou reports no conflicts of interest. Dr. Michele Fornaro reports no conflicts of interest. Dr. Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Galenica, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sage, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Generalitat de Catalunya (PERIS), the Spanish Ministry of Science, Innovation and Universities (CIBERSAM), EU Horizon 2020, and the Stanley Medical Research Institute. Dr. Brendon Stubbs reports no conflicts of interest. Dr. Marco Solmi reports no conflicts of interest. Dr. Andre Carvalho reports no conflicts of interest. Funding Information: We are grateful to all participants who took part in the individual studies included in our systematic review and meta-analysis. Dr. Lícia P. Luna reports no conflicts of interest. Dr. Joaquim Radua reports no conflicts of interest. Dr. Lydia Fortea reports no conflicts of interest. Dr. Gisela Sugranyes reports no conflicts of interest. Dr. Adriana Fortea reports no conflicts of interest. Dr. Paolo Fusar-Poli has received grant fees from Lundbeck and honoraria fees from Lundbeck, Angelini and Menarini, outside the current work. Dr. Lee Smith reports no conflicts of interest. Dr. Joseph Firth is currently supported by a University of Manchester Presidential Fellowship (P123958) and a UK Research and Innovation Future Leaders Fellowship (MR/T021780/1) and has received support from a NICM-Blackmores Institute Fellowship. Dr. Jae Il Shin reports no conflicts of interest. Dr. Andre R. Brunoni reports no conflicts of interest. Dr. Muhammad I. Husain reports no conflicts of interest. Dr. Muhammad O. Husian reports no conflicts of interest. Dr. Haris I. Sair reports no conflicts of interest. Dr. Walber O. Mendes reports no conflicts of interest. Luiz Ricardo A. Uchoa reports no conflicts of interest. Dr. Michael Berk is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). Dr. Michael Berk has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. Dr. Michael Maes reports no conflicts of interest. Dr. Zafiris J Daskalakis reports no conflicts of interest. Dr. Sophia Frangou reports no conflicts of interest. Dr. Michele Fornaro reports no conflicts of interest. Dr. Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Galenica, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sage, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Generalitat de Catalunya (PERIS), the Spanish Ministry of Science, Innovation and Universities (CIBERSAM), EU Horizon 2020, and the Stanley Medical Research Institute. Dr. Brendon Stubbs reports no conflicts of interest. Dr. Marco Solmi reports no conflicts of interest. Dr. Andre Carvalho reports no conflicts of interest. Publisher Copyright: © 2022 Elsevier Inc.
PY - 2022/7/13
Y1 - 2022/7/13
N2 - Neuroimaging findings in people at either genetic risk or at clinical high-risk for psychosis (CHR-P) or bipolar disorder (CHR-B) remain unclear. A meta-analytic review of whole-brain voxel-based morphometry (VBM) and functional magnetic resonance imaging (fMRI) studies in individuals with genetic risk or CHR-P or CHR-B and controls identified 94 datasets (N = 7942). Notwithstanding no significant findings were observed following adjustment for multiple comparisons, several findings were noted at a more liberal threshold. Subjects at genetic risk for schizophrenia or bipolar disorder or at CHR-P exhibited lower gray matter (GM) volumes in the gyrus rectus (Hedges' g = −0.19). Genetic risk for psychosis was associated with GM reductions in the right cerebellum and left amygdala. CHR-P was associated with decreased GM volumes in the frontal superior gyrus and hypoactivation in the right precuneus, the superior frontal gyrus and the right inferior frontal gyrus. Genetic and CHR-P were associated with small structural and functional alterations involving regions implicated in psychosis. Further neuroimaging studies in individuals with genetic or CHR-B are warranted.
AB - Neuroimaging findings in people at either genetic risk or at clinical high-risk for psychosis (CHR-P) or bipolar disorder (CHR-B) remain unclear. A meta-analytic review of whole-brain voxel-based morphometry (VBM) and functional magnetic resonance imaging (fMRI) studies in individuals with genetic risk or CHR-P or CHR-B and controls identified 94 datasets (N = 7942). Notwithstanding no significant findings were observed following adjustment for multiple comparisons, several findings were noted at a more liberal threshold. Subjects at genetic risk for schizophrenia or bipolar disorder or at CHR-P exhibited lower gray matter (GM) volumes in the gyrus rectus (Hedges' g = −0.19). Genetic risk for psychosis was associated with GM reductions in the right cerebellum and left amygdala. CHR-P was associated with decreased GM volumes in the frontal superior gyrus and hypoactivation in the right precuneus, the superior frontal gyrus and the right inferior frontal gyrus. Genetic and CHR-P were associated with small structural and functional alterations involving regions implicated in psychosis. Further neuroimaging studies in individuals with genetic or CHR-B are warranted.
KW - Bipolar disorder
KW - Meta-analysis
KW - Neuroimaging
KW - Psychiatry
KW - Psychosis
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85125711346&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2022.110540
DO - 10.1016/j.pnpbp.2022.110540
M3 - Review article
C2 - 35240226
AN - SCOPUS:85125711346
SN - 0278-5846
VL - 117
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
M1 - 110540
ER -